Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
Takeda has announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 […]
Global Sarcoma Therapy Now Approved For New Zealand Patients
Independent biopharmaceutical company, Specialised Therapeutics (ST), is pleased to announce that its portfolio therapy to […]
ARX517 Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer
Ambrx Biopharma today announced encouraging initial data from its ongoing Phase 1 trial investigating ARX517, […]
LIfT BioSciences and Minaris Regenerative Medicine Enter into a Development and Manufacturing Partnership
LIfT BioSciences, a pioneering pre-clinical stage company moving into first-in-human trials with an allogeneic neutrophil […]
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
UroGen Pharma, a biotech company dedicated to developing and commercializing innovative treatment of urothelial and […]
BiPER Therapeutics Raises €1.25 Million in Seed Funding to Develop First-in-class Small Molecules to Treat Gastrointestinal Cancers
BiPER Therapeutics, a preclinical biotechnology company developing first-in-class drug candidates targeting BiP protein to treat […]
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
Fusion Pharmaceuticals, a clinical-stage oncology company focused on developing next-generation targeted alpha therapies as precision […]
LegoChem Biosciences Signs License Agreement to Acquire First-in-class Antibody From Elthera
LegoChem Biosciences announced on February 13, 2023 a license agreement with Elthera AG, a biotechnology […]
B dot Medical to Install Ultra-compact Proton Therapy System at Thammasat University in Thailand
B dot Medical and Thammasat University, a leading national university in Thailand, have signed a memorandum […]
Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification
Phio Pharmaceuticals, a clinical-stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more